drugset / Trial / NCT04455594
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, controlled, phase II study assessing the efficacy and safety of Almonertinib compared Erlotinib or platinum doublet chemotherapy (carboplatin or cisplatin + pemetrexed) as neoadjuvant therapy to EGFRm+ IIIA-N2 NSCLC patients.
Timeline
- Start
- 2020-10
- Primary completion
- 2023-01
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | 110 mg | Oral |
| Comparator | Carboplatin | Small molecule | 5 unknown | — |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Comparator | Erlotinib | Small molecule | 150 mg | Oral |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | — |